BlackRock’s Iterum Therapeutics ITRM Stock Holding History

BlackRock’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-816	Closed	-$7K	–	5818
2021 Q3	$7K	Hold	816	–	–	﹤0.01%	5462
2021 Q2	$28K	Buy	+816	New	+$17.7K	﹤0.01%	5252

Other funds holding ITRM

CPX

Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

BlackRock's ITRM Position: Q4 2021 in Review

BlackRock sold out of Iterum Therapeutics (ITRM) in Q4 2021, closing a stake of 816 shares — an estimated $7K sold.

BlackRock first reported a position in ITRM in Q2 2021 and held it in 2 quarters. The position peaked at $28K in Q2 2021. 44 funds tracked by Wall St. Rank hold ITRM as of Q4 2021.

BlackRock reported no remaining Iterum Therapeutics position as of Q4 2021 after selling out during the quarter.
BlackRock sold 816 Iterum Therapeutics shares in Q4 2021, an estimated $7K.
BlackRock first reported a position in Iterum Therapeutics in Q2 2021 and held it in 2 quarters.
BlackRock's Iterum Therapeutics position peaked at $28K in Q2 2021.
44 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q4 2021.

Based on BlackRock's 13F filing for Q4 2021, filed 10 Feb 2022.